March 23 - Gilead Sciences is approaching a transaction to acquire Ouro Medicines, a small biotechnology company developing treatments for immune disorders, in a deal valued at as much as $2 billion, according to multiple people familiar with the matter.
Under the reported terms, Gilead would pay the privately held company’s investors roughly $1.5 billion in cash up front. In addition, the agreement would include at least $500 million in contingent payments that would become payable if Ouro meets certain clinical trial milestones.
People with knowledge of the discussions indicated the acquisition could be announced within days, but they cautioned that both the timing and the final commercial terms remain subject to change. The companies have not provided public comment on the reported negotiations; Gilead and California-based Ouro Medicines did not immediately respond to requests for comment.
The proposed structure combines a significant upfront cash consideration with milestone-based earnouts tied to clinical development progress. That mix mirrors common dealmaking patterns in the pharmaceuticals and biotech sectors where acquirers seek to balance near-term investment with contingent upside linked to clinical outcomes.
Investors and market participants monitoring the situation will likely watch for an official announcement to confirm the headline valuation, the precise structure of milestone payments, and any adjustments to timing or terms that could arise before a definitive agreement is signed.
Summary
Gilead is reportedly close to acquiring Ouro Medicines for up to $2 billion, consisting of about $1.5 billion in upfront cash and at least $500 million tied to clinical milestones. An announcement could come in the coming days, though the timing and terms remain subject to change. Both companies have not commented on the reported talks.
Key points
- Gilead is nearing a transaction to buy Ouro Medicines for up to $2 billion.
- The reported consideration includes roughly $1.5 billion upfront in cash plus at least $500 million contingent on clinical trial milestones.
- Sectors affected include biotechnology and pharmaceuticals, with potential implications for market activity around related healthcare equities.
Risks and uncertainties
- The timing and final terms of the deal could change before any announcement, creating uncertainty for investors and counterparties in the biotech and pharmaceutical sectors.
- At least $500 million of the consideration is contingent on clinical trial milestones, meaning the ultimate price depends on future trial outcomes and development progress.
- There has been no immediate comment from Gilead or Ouro Medicines, leaving open questions about finalized negotiations and public disclosure.